Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol’s Oncology Strategy: Stay In The Lead On Immunotherapy

Executive Summary

At the recent ASCO meeting, Bristol’s immunotherapies had a very high profile, paving the way for further development of the company’s PD-1/CTLA-4 combination and development of checkpoint inhibitors in new tumor types.

Advertisement

Related Content

Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register